Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMYMP) R&D In Process (2021 - 2025)

Historic R&D In Process for Bristol Myers Squibb (BMYMP) over the last 5 years, with Q4 2025 value amounting to $1.4 billion.

  • Bristol Myers Squibb's R&D In Process rose 454333.33% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year decrease of 7216.78%. This contributed to the annual value of $3.7 billion for FY2025, which is 7217.53% down from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's R&D In Process is $1.4 billion, which was up 454333.33% from $633.0 million recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year R&D In Process high stood at $12.9 billion for Q1 2024, and its period low was $6.0 million during Q1 2021.
  • In the last 5 years, Bristol Myers Squibb's R&D In Process had a median value of $225.0 million in 2024 and averaged $999.1 million.
  • Its R&D In Process has fluctuated over the past 5 years, first surged by 1716533.33% in 2024, then plummeted by 9854.82% in 2025.
  • Bristol Myers Squibb's R&D In Process (Quarter) stood at $89.0 million in 2021, then crashed by 41.57% to $52.0 million in 2022, then soared by 1053.85% to $600.0 million in 2023, then crashed by 95.0% to $30.0 million in 2024, then skyrocketed by 4543.33% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q4 2025, $633.0 million for Q3 2025, and $1.5 billion during Q2 2025.